A phase I, open-label study of intravenous human dental pulp stem cells (NestaCell®) at two dose levels in patients with Huntington’s disease.

Providing evidence-based psychiatric care and advanced TMS therapy for adults experiencing depression, anxiety, and treatment-resistant mood disorders.